SCHEMBL2670347

SCHEMBL2670347

CC(C)(C)OC(=O)N[C@@]12CCC[C@H]1CC(F)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
BTK Q06187 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
DPP8 Q6V1X1 3/20 0.33
DPP9 Q86TI2 3/20 0.33
GAA P10253 2/20 0.33
EPHX1 P07099 1/20 0.32
CTSK P43235 3/20 0.32
EPHX2 P34913 1/20 0.31
CACNA1H O95180 1/20 0.31
CTSL P07711 1/20 0.30
HDAC4 P56524 1/20 0.30
HDAC1 Q13547 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14432062 0.82 PSEN1 (0.41) MEN1MAPK1KMT2ABTKPSEN1
SCHEMBL18477541 0.80 PSEN1 (0.42) MEN1MAPK1KMT2ABTKPSEN1
SCHEMBL2670376 0.77 MEN1 (0.37) MEN1MAPK1KMT2ABTKDPP8
SCHEMBL4748874 0.77 MEN1 (0.37) MEN1MAPK1KMT2ABTKDPP8
SCHEMBL12808831 0.76 MEN1 (0.36) MEN1MAPK1KMT2ABTKPSEN1
SCHEMBL4748058 0.74 PSEN1 (0.36) MEN1MAPK1KMT2ABTKPSEN1
SCHEMBL2670229 0.74 PSEN1 (0.36) MEN1MAPK1KMT2ABTKPSEN1
SCHEMBL2670185 0.74 PSEN1 (0.36) MEN1MAPK1KMT2ABTKPSEN1
Ammonia Solution, Strong SCHEMBL28412752 0.74 MEN1 (0.47) MEN1MAPK1KMT2ABTKGAA
SCHEMBL2670088 0.73 GAA (0.38) MEN1MAPK1KMT2ABTKPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140142096-A1 Fused Substituted Aminopyrrolidine Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-22 US disclosed
US-8618094-B2 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-12-31 US disclosed
EP-2097400-B1 FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2013-07-03 EP disclosed
US-20130029977-A9 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2013-01-31 US disclosed
EP-2540715-A1 Fused substituted aminopyrrolidine derivative Daiichi Sankyo Company, Limited (JP) 2013-01-02 EP disclosed
US-20120108582-A1 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108582-A1 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 MEN1 3591/4885MAPK1 2614/4885KMT2A 2847/4885
US-20140142096-A1 Fused Substituted Aminopyrrolidine Derivative NQO2, QDPR, IL4I1 MEN1 3591/4885MAPK1 2614/4885KMT2A 2847/4885
US-20130029977-A9 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 MEN1 3591/4885MAPK1 2614/4885KMT2A 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.